Real-world study examines breast cancer drug's effectiveness outside clinical trials
NCT ID NCT06784921
First seen Jan 17, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study will review medical records of 200 patients in China with HER2-negative metastatic breast cancer who received sacituzumab govitecan. Researchers want to see how long the drug keeps cancer from growing and how well patients tolerate it. The goal is to understand real-world outcomes beyond controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan
What this could lead to
If successful, this study could confirm that sacituzumab govitecan is effective and safe for HER2-negative metastatic breast cancer patients in real-world settings.
What could go wrong
This is a retrospective study, so it looks at past data and cannot prove cause and effect. Results may not apply to all patients or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.